PEGNasdaq CopenhagenBiotechnologyIFRS · DKK

Pharma Equity Group A/S

Pharma Equity Group A/S is a Danish listed company based in Hørsholm. The available filing excerpt confirms it prepares IFRS financial statements and presents consolidated interim reporting in Danish kroner, but it does not provide enough information to verify the group’s operating business, products, or end markets from the supplied context.

Kysy yhtiöstä
Liikevaihto0,0milj. DKK
Liikevoitto (EBIT)−17,2milj. DKK
+19,3 %v/v
Nettotulos−25,4milj. DKK
−3,9 %v/v
Vapaa kassavirta−17,7milj. DKK
+22,7 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2022–2025

−25−20−15−10−50milj. DKK2022: 0,00 milj. DKK2022: EBIT −11 milj. DKK20222023: 0,00 milj. DKK2023: EBIT −21 milj. DKK20232024: 0,00 milj. DKK2024: EBIT −21 milj. DKK20242025: 0,00 milj. DKK2025: EBIT −17 milj. DKK20250,00−17
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Pharma Equity Group A/S

Liiketoiminta

Osuus liikevaihdosta

{"• Insufficient information to verify operating products or services","• IFRS interim and annual reporting in Danish kroner","• Listed-company corporate structure in Denmark"}

Unverified operating business100 %

Operating products or services are not disclosed in the provided context.

Asiakkaat

The provided information does not disclose identifiable customer groups, buyers, or end markets. As a result, the company’s revenue model and customer base cannot be verified from the supplied excerpts. Any further segmentation would be speculative.

Undisclosed

No customer or end-market disclosure was provided in the available context.

Maantiede

Pharma Equity Group A/S is identified as a Danish company, and the interim report was approved in Hørsholm. Beyond Denmark, the supplied excerpts do not disclose operating countries, sales regions, or manufacturing locations, so broader geographic exposure cannot be verified.

Riskit

Because the company’s operating business is not described in the available context, company-specific business risks cannot be reliably identified. The main verifiable risk signals are disclosure-related: investors cannot assess customer concentration, geographic exposure, product dependence, or operating leverage from the excerpt alone.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Undisclosed operating model1Unknown customer concentration2
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Undisclosed operating modelVaikutus: KorkeaTodennäköisyys: Korkea

    The excerpt does not identify products, customers, or markets, limiting risk assessment.

    Kohdistuu: Business model visibility

  2. Unknown customer concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Without customer disclosure, dependence on a small number of buyers cannot be evaluated.

    Kohdistuu: Revenue concentration

Kysy Clarifolta: Pharma Equity Group A/S

Kirjanpito

Harkinnanvaraiset erät
IFRS reporting basis

The company reports under IFRS as adopted by the EU, which frames recognition and measurement.

Vaikutus: Affects comparability and the presentation of the interim financial statements

Functional and presentation currency

Financial statements are presented in Danish kroner (DKK).

Vaikutus: Currency presentation affects translation and investor interpretation

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

CDT Equity Inc.

CDT · Pharmaceutical Preparations

Powerdyne International, Inc.

PWDY · Services-Computer Processing & Data Preparation

PharmaCyte Biotech, Inc.

PMCB · Biological Products, (No Diagnostic Substances)

SynAct Pharma

SYNACT · Health Care

Drugs Made In America Acquisition Corp.

DMAA · Blank Checks

Bio Green Med Solution, Inc.

BGMS · Wholesale-Durable Goods, NEC

Päivitetty: 24.10.2026

Pharma Equity Group A/S (XCSE) – Biotechnology | Analyysi – Clarifo